{"name": "Blueprint Medicines",
 "permalink": "blueprint-medicines",
 "crunchbase_url": "http://www.crunchbase.com/company/blueprint-medicines",
 "homepage_url": "http://www.blueprintmedicines.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "media@blueprintmedicines.com",
 "phone_number": "617-585-2033",
 "description": "",
 "created_at": "Tue Apr 12 02:24:59 UTC 2011",
 "updated_at": "Fri May 25 06:05:54 UTC 2012",
 "overview": "\u003Cp\u003EBlueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation\u00e2\u201e\u00a2 Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data \u00e2\u20ac\u0153revolution\u00e2\u20ac\u009d: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       31],
      "assets/images/resized/0013/0131/130131v1-max-150x150.png"],
     [[250,
       52],
      "assets/images/resized/0013/0131/130131v1-max-250x250.png"],
     [[300,
       63],
      "assets/images/resized/0013/0131/130131v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Chris",
      "last_name": "Varma",
      "permalink": "chris-varma-2",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$40M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.blueprintmedicines.com/pdf/Blueprint-Launch-PR.pdf",
    "source_description": "Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments",
    "raised_amount": 40000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 4,
    "funded_day": 11,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Third Rock Ventures",
         "permalink": "third-rock-ventures-2",
         "image":
          {"available_sizes":
            [[[150,
               78],
              "assets/images/resized/0005/0700/50700v1-max-150x150.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-250x250.png"],
             [[205,
               107],
              "assets/images/resized/0005/0700/50700v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Fidelity Biosciences",
         "permalink": "fidelity-biosciences-2",
         "image":
          {"available_sizes":
            [[[150,
               50],
              "assets/images/resized/0005/0044/50044v1-max-150x150.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-250x250.png"],
             [[233,
               79],
              "assets/images/resized/0005/0044/50044v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [],
 "milestones":
  [{"description": "Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate",
    "stoned_year": 2012,
    "stoned_month": 5,
    "stoned_day": 24,
    "source_url": "http://www.blueprintmedicines.com/pdf/Blueprint_Fidelity_PR_42512_Final.pdf",
    "source_text": "",
    "source_description": "Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Blueprint Medicines",
      "permalink": "blueprint-medicines"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}